CorMedix
CRMD
80 hedge funds and large institutions have $59.4M invested in CorMedix in 2021 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 26 increasing their positions, 25 reducing their positions, and 6 closing their positions.
17% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 6
8% more capital invested
Capital invested by funds: $55M → $59.4M (+$4.44M)
3.25% more ownership
Funds ownership: 31% → 34.25% (+3.3%)
1% more funds holding
Funds holding: 79 → 80 (+1)
4% more repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 25
1% more call options, than puts
Call options by funds: $364K | Put options by funds: $361K
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Nomura Holdings
Tokyo,
Japan
|
+$7.78M |
| 2 |
Goldman Sachs
New York
|
+$177K |
| 3 |
Barclays
London,
United Kingdom
|
+$151K |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$136K |
| 5 |
Wells Fargo
San Francisco,
California
|
+$109K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$1.07M |
| 2 |
Renaissance Technologies
New York
|
-$549K |
| 3 |
Two Sigma Advisers
New York
|
-$375K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$137K |
| 5 |
Two Sigma Investments
New York
|
-$121K |
CRMD Hedge Fund Activity: Q4 2021 in Review
80 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in CorMedix (CRMD) for Q4 2021, worth a combined $59.4M — up 8.1% from $55M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new CRMD positions and 6 closed out — a net gain of 1 holder — while 26 added to existing stakes and 25 trimmed.
The largest buyer was Nomura Holdings, adding an estimated $7.78M. The largest seller was Morgan Stanley, cutting an estimated $1.07M.
- 80 institutional investors held CorMedix (CRMD) as of Q4 2021, up from 79 in Q3 2021.
- Funds reported $59.4M of CorMedix stock for Q4 2021, up 8.1% quarter-over-quarter.
- 7 funds opened new CorMedix positions in Q4 2021 and 6 closed out, a net change of +1 holder.
- The largest CorMedix buyer in Q4 2021 was Nomura Holdings, an estimated $7.78M added.
- The largest CorMedix seller in Q4 2021 was Morgan Stanley, an estimated $1.07M sold.
Based on aggregated 13F filings for Q4 2021.